Retatrutide
4 mg · ITT
Obesity, no T2D
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
TRIUMPH-1 · NCT05929066
Disease Pipeline Tools Obesity
Obesity
Programs, trials, and reported weight change for obesity and overweight.
Obesity pipeline
Each card is one trial arm against its own placebo, at the weeks the source reports. The default card is the highest stated milligram dose.
11 cards with an ITT estimand. 22 cards have a weight figure and no stated estimand.
4 mg · ITT
Obesity, no T2D
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
TRIUMPH-1 · NCT05929066
9 mg · ITT
Obesity, no T2D
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
TRIUMPH-1 · NCT05929066
12 mg · ITT
Obesity, no T2D
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
TRIUMPH-1 · NCT05929066
2.4 mg · ITT
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
STEP 1 · NCT03548935
7.2 mg · ITT
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
STEP UP · NCT05646706
2.4 mg · ITT
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
STEP UP · NCT05646706
3.6 mg · ITT
Obesity + T2D
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
SYNCHRONIZE-1 · NCT06066515
6.0 mg · ITT
Obesity + T2D
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
SYNCHRONIZE-1 · NCT06066515
5 mg · ITT
Obesity, no T2D
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
SURMOUNT-1 · NCT04184622
10 mg · ITT
Obesity, no T2D
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
SURMOUNT-1 · NCT04184622
15 mg · ITT
Obesity, no T2D
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
SURMOUNT-1 · NCT04184622
These arms report a weight change and do not name ITT or efficacy. They stay out of both estimand sets.
cagrilintide 2.4 mg and semaglutide 2.4 mg · n/r
Obesity, no T2D
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
REDEFINE 1 · NCT05567796
2.5 mg · n/r
Obesity, no T2D
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
VENTURE · NCT06068946
15 mg · n/r
Obesity, no T2D
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
VENTURE · NCT06068946
Dose n/r · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) · NCT02635386
Dose n/r · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) · NCT02635386
Dose n/r · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) · NCT02635386
Dose n/r · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) · NCT02635386
Dose n/r · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) · NCT02635386
Dose n/r · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
ECHO · NCT02664441
3.0mg · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
3.0mg · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
3.0 mg · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes · NCT01272232
1.8 mg · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes · NCT01272232
Dose n/r · n/r
T2D only
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) · NCT01234649
Dose n/r · n/r
Obesity + T2D
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
SAXAPCOS · NCT03480022
10 mg · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight · NCT06124807
16 mg · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight · NCT06124807
6 mg · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight · NCT06124807
Dose n/r · n/r
Bardet Biedl Syndrome (BBS); Alström Syndrome...
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
Dose n/r · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity · NCT03287960
Dose n/r · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity · NCT02896192
Dose n/r · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway · NCT04963231
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.